Graybug Vision initiated a phase 2b study of GB-102, a pan-VEGF receptor inhibitor and potential twice-per-year therapy, for the treatment of wet age-related macular degeneration.
The 12-month, three-arm randomized controlled ALTISSIMO study is evaluating GB-102 in 1 mg and 2 mg dose levels administered every 6 months vs. aflibercept 2 mg administered every 2 months. One hundred sixty patients with wet AMD will be enrolled at more than 100 clinical centers in the United States, according to a press release.
The therapy is designed to reduce the treatment burden and (Read more...)
Uncategorized